Fox Hill Wealth Management Makes New Investment in DaVita Inc. $DVA

Fox Hill Wealth Management bought a new position in shares of DaVita Inc. (NYSE:DVA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 7,212 shares of the company’s stock, valued at approximately $1,605,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Root Financial Partners LLC boosted its position in DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after buying an additional 105 shares during the period. Caitlin John LLC purchased a new position in shares of DaVita during the fourth quarter worth approximately $34,000. Sankala Group LLC bought a new stake in shares of DaVita during the fourth quarter valued at approximately $39,000. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita in the second quarter valued at approximately $43,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of DaVita in the fourth quarter valued at approximately $45,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is currently owned by company insiders.

DaVita Price Performance

DVA opened at $180.72 on Friday. The firm has a market capitalization of $11.53 billion, a PE ratio of 14.79, a price-to-earnings-growth ratio of 0.46 and a beta of 0.88. The business’s 50-day moving average is $211.96 and its two-hundred day moving average is $183.05. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. During the same period last year, the business earned $2.95 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 14.57 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on DVA shares. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Oppenheimer set a $220.00 target price on shares of DaVita in a report on Friday, August 7th. Raymond James Financial set a $220.00 target price on shares of DaVita in a research report on Friday, August 7th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and increased their price objective for the company from $201.00 to $220.00 in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $221.75.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.